On the Need for Better Information from Randomized Clinical Trials in Oncology

Cancer patients frequently seek information from their oncologists regarding the anticipated outcomes of their treatment. They commonly inquire about the potential for a cure and the likelihood of achieving it, as well as whether the treatment will prolong their life and, if so, by how much. In oncology, randomized controlled trials play a pivotal role in informing treatment decisions. It is essential that published randomized controlled trials provide comprehensive data to enable clinicians to deliver precise and reliable information to patients. The concept of the Hazard Ratio (HR) can be challenging for many oncologists and is often misunderstood in terms of its implications for risk. Thus, incorporating both relative and absolute risk metrics in addition to hazard ratios could substantially enhance patient care. This consideration is crucial not only for patients and oncologists but also for policymakers within public health systems.